Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
The limitations of this study, including its retrospective design and the difficulty in separating direct drug effects from the consequences of weight loss, underscore the need for further investigation
However, extensive cardiovascular outcome trials have demonstrated that GLP-1 receptor agonists are safe and may even reduce cardiovascular risk
These potential benefits include preserved eGFR, reversal of bone-mineral disorder, decreased risk of progression to dialysis, reduced urinary protein loss, decreased blood phosphate, and reduced all-cause mortality
For patients experiencing non-emergent back pain during GLP-1-based therapy, a systematic approach to management can often provide relief while allowing continuation of beneficial metabolic treatment
doi:10.1126/scitranslmed.3009759 114
US$ 23.99
US$ 24.88
US$ 28.95
US$ 26.31
US$ 24.03
US$ 26.59
US$ 22.01
US$ 28.79
